Medicine and Pharmacology

Article
Medicine and Pharmacology
Oncology and Oncogenics

Pantelie Nicolcescu

,

Maria Filofteia Mercuț

,

Ionela Mihai

,

Mihai Rusu

,

Adrian Hașegan

Abstract: Background/Objectives: Blood-count inflammatory indices may mark aggressive renal cell carcinoma (RCC), but their association with adverse pathology may reflect tumour size, anaemia or C-reactive protein (CRP). Methods: In a retrospective cohort of patients undergoing nephrectomy for RCC (2016–2025), five preoperative indices were related to pT3–4 stage and grade 3–4 in models fitted in the same patients, with adjustment for haemoglobin, tumour size (spline) and CRP, multiple imputation and assessment of incremental value. Results: Of 256 patients, 55/232 had pT3–4 and 71/235 grade 3–4 tumours. Per 1-SD increase in log systemic immune-inflammation index (SII), the odds ratio for pT3–4 was 2.21 (1.41–3.47) after adjustment for haemoglobin and size, 2.01 (1.07–3.76) with CRP added (137 patients) and 1.97 (1.27–3.05) after imputation. Adding SII to a model with tumour size increased the optimism-corrected AUC from 0.75 to 0.78. No leucocyte-based index was associated with grade after adjustment for haemoglobin. Conclusions: SII was associated with locally advanced RCC independently of tumour size, haemoglobin and CRP, but added little discrimination once tumour size was known. Validation against radiological staging is required.

Article
Medicine and Pharmacology
Oncology and Oncogenics

Ji Li

,

Pi Liu

,

Wei Zhang

,

Qiuyang Zhang

Abstract: Background/Objectives: Esophageal squamous cell carcinoma (ESCC) is a predominant subtype of esophageal cancer in East Asia and is associated with high cancer-related mortality. CCAAT/enhancer-binding protein beta (CEBPB) is implicated in tumor progression and chemoresistance; however, its functional role and therapeutic potential in ESCC remain poorly understood. This study aimed to investigate the role of CEBPB in ESCC progression and cisplatin resistance and to explore its potential as a therapeutic target. Methods: CEBPB expression and its clinical significance were evaluated using public datasets and human ESCC tissue arrays. A human reflux model, esophageal organoids, and ESCC cell lines were used to investigate the effects of CEBPB on epithelial proliferation, differentiation, and cisplatin sensitivity. CEBPB gain- and loss-of-function experiments, apoptosis assays, pathway gene profiling and luciferase reporter assays were performed to assess its biological functions and transcriptional activity. The effects of combined cisplatin and itraconazole treatment were evaluated in ESCC cells. Statistical analyses were performed using unpaired t-tests or one-way ANOVA, and survival was analyzed using the Kaplan–Meier method and log-rank test. Results: In non-neoplastic esophageal tissues, increased CEBPB expression was associated with reflux-induced basal cell hyperplasia. Organoid experiments demonstrated that CEBPB promoted cell proliferation while suppressing basal cell differentiation. CEBPB expression was significantly elevated during ESCC progression, and higher expression was associated with poorer overall survival (P < 0.05). In cultured ESCC cells, CEBPB enhanced cell growth and survival by directly regulating the transcription of the anti-apoptotic gene MCL1. Elevated CEBPB expression conferred resistance to cisplatin, whereas CEBPB knockdown increased apoptosis and reduced MCL1 expression in cisplatin-resistant ESCC cells. Furthermore, combined treatment with cisplatin and itraconazole promoted apoptosis in cisplatin resistant and naïve ESCC cells compared with cisplatin treatment alone. Conclusions: CEBPB promotes ESCC progression and contributes to cisplatin resistance, at least in part, through transcriptional regulation of MCL1. Targeting CEBPB in combination with cisplatin may represent a potential therapeutic strategy for overcoming chemoresistance in ESCC and may have broader relevance across multiple cancer types in which CEBPB contributes to disease progression and drug resistance.

Article
Medicine and Pharmacology
Oncology and Oncogenics

Olakunle Olorunkemi

Abstract: Purpose. About one in five patients with colorectal cancer presents with metastatic disease, and many receive no recorded anticancer treatment. We described treatment patterns and examined survival differences by race/ethnicity, county income and rurality among adults with Stage IV colorectal cancer. Methods. Retrospective cohort of adults aged 20 years or older diagnosed in 2018-2023 in the Surveillance, Epidemiology, and End Results (SEER) program (n = 44,507 analyzed). Treatment was grouped as surgery plus chemotherapy, chemotherapy without surgery, surgery without chemotherapy, radiation only, or no recorded treatment. We used logistic regression, Kaplan-Meier methods and sequentially adjusted Cox models (3-month landmark analysis for treatment). Results. Overall, 24.8% had no recorded treatment (crude median survival 1 month). Age 75 or older versus under 50 carried the highest odds of no recorded treatment (odds ratio 7.26, 95% CI 6.56-8.03); odds were also higher for Black patients (1.31, 1.22-1.41). Three-year survival was 18.6% for Black versus 23.1% for White patients. Adjustment for treatment group attenuated the Black-White hazard ratio from 1.18 to 1.13; income and rurality estimates were unchanged. The Black-White difference was largest under age 50 (hazard ratio 1.45, 1.31-1.60) and absent at 75 and older (1.01, 0.95-1.08). Conclusions. About one in four adults with Stage IV colorectal cancer had no recorded treatment, mostly older patients. Survival differences by race/ethnicity, county income and rurality persisted after adjustment, with only slight attenuation of the Black-White difference after adjustment for recorded treatment.

Article
Medicine and Pharmacology
Oncology and Oncogenics

Ovidiu Farc

,

Ioana Berindan-Neagoe

,

Victor Cristea

Abstract: Bulk transcriptomic studies in colon cancer have primarily focused on molecular subtyping and prognostic gene signatures. While these approaches have refined tumor classification, they provide limited insight into the higher-order organization of oncogenic programs that shape tumor behavior. This study performs systems-level analysis to define the hierarchical architecture of transcriptional networks in colon cancer and identify functional axes that characterize tumor biology and may have clinical significance. Transcriptomics data were downloaded from TCGA-COAD for 458 colon cancer patients. We performed differential RNA-sequencing (DESeq2) analysis, followed by weighted gene co-expression network analysis (WGCNA). We integrated network topology, functional clustering and module organization to identify higher-order transcriptional axes. Transcriptomics data were integrated with clinical parameters. Tumor tissue showed proliferation-associated modules and enhanced immune network connectivity. Co-expression analysis identified four major functional axes defining its systems-level architecture: proliferative oncogenic signaling, metabolism, stromal organization and invasion, and immune responses. The proliferative and stromal axes were aassociated with advanced disease, whereas immune-related modules correlated with favorable clinical outcomes. The association was weak, but showed consistent directional pattern. Colon tumorigenesis appears to involve a coordinated transition between distinct network states characterized by the emergence of coordinated functional programs rather than isolated pathway activation. Systems-level immune and oncogenic polarization axes may provide a framework to understand clinical heterogeneity and to design biologically grounded network approaches.

Article
Medicine and Pharmacology
Oncology and Oncogenics

Eva Ćirić

,

Tjaša Augustinčič

,

Jasna But-Hadžić

Abstract: The optimal integration of systemic therapy and comprehensive local treatment in non-oncogene-addicted de novo oligometastatic non-small cell lung cancer (NSCLC) remains uncertain. We retrospectively analysed a nationwide cohort of 107 patients with synchronous or metachronous de novo oligometastatic NSCLC treated at a single national referral centre between 2018 and 2022. All oligometastatic lesions received stereotactic body radiotherapy or stereotactic radiosurgery, while the primary tumour was definitively treated where applicable. Median follow-up was 65.2 months, median overall survival (OS) 22.6 months, and median progression-free survival (PFS) 10.1 months. On multivariable analysis, immunotherapy-based systemic treatment was associated with improved PFS versus chemotherapy-based treatment (adjusted hazard ratio [aHR] 0.46, 95% CI 0.22–0.96; p=0.038). Conventional radiotherapy ± chemotherapy to the primary tumour, compared with surgery or SBRT, was associated with worse OS (aHR 2.00, 95% CI 1.22–3.27; p=0.006) and PFS (aHR 1.99, 95% CI 1.23–3.20; p=0.005). Metastatic-lesion BED₁₀ ≥60 Gy was associated with improved PFS (aHR 0.54, 95% CI 0.34–0.84; p=0.006). These findings support further investigation of integrated systemic and comprehensive local treatment strategies in this population.

Review
Medicine and Pharmacology
Oncology and Oncogenics

Ahmad R. Alsayed

,

Heba A Khader

,

Luai Z. Hasoun

,

Shiraz Halloush

,

Mustafa Mohammed Al-Bayati

,

Mohannad Al-Qaiseiah

,

Mohanad Al-Darraji

,

Suliman Al-Shurafa

,

Nouraldeen Shujrawi

,

Muath Alsarafandi

Abstract: Cancer remains one of the leading causes of morbidity and mortality worldwide, necessitating continuous advances in therapeutic strategies to improve treatment efficacy and patient outcomes. Over recent decades, cancer management has evolved from conventional cytotoxic approaches toward more sophisticated, individualized interventions that target specific molecular alterations and harness the immune system. This review provides a comprehensive overview of the paradigm shift in cancer treatment, tracing the evolution from conventional chemotherapy to modern precision oncology and immunotherapy. We examine traditional diagnostic staging and highlight the integration of liquid biopsies and advanced biosensor technologies for real-time, non-invasive clinical monitoring. The review explores the mechanistic pillars of cell cycle-specific and non-specific chemotherapeutic agents, alongside the complex multidrug resistance pathways and metabolic rewiring that drive chemoresistance. We also evaluate the growing efficacy of targeted treatments, including small-molecule kinase inhibitors and antibody-drug conjugates, and detail the transformative clinical impact of immune checkpoint inhibitors, CAR-T cell therapies, and therapeutic vaccines. Emphasizing personalized medicine, we discuss the critical role of pharmacogenomics, biomarker-guided therapies, and the integration of artificial intelligence and quantitative systems pharmacology in optimizing dosing. Finally, we address future directions, including CRISPR-engineered cellular therapies and the modulation of the hypoxic tumor microenvironment using natural phytochemicals.

Review
Medicine and Pharmacology
Oncology and Oncogenics

Vladimir F. Niculescu

Abstract: In previous cancer research, cancer stem cells (CSCs) have generally been defined as undifferentiated, whereas somatic bulk tumor cells —by analogy with the somatic cells of the human body—have been considered differentiated and, in some contexts, referred to as non-stem cells. However, somatic cancer cells are not differentiated progeny generated through asymmetric cell division of self-renewing CSCs. Rather, they arise through cellular plasticity and mesenchymal-to-epithelial transition (MET) from CSCs, whereas new CSC clones and sublines can arise through the opposing epithelial-to-mesenchymal transition (EMT). These processes therefore do not represent conventional differentiation and dedifferentiation, but rather an ancestral form of “germ-to-soma” and “soma-to-germ” conversion that may serve to maintain proliferation and survival in unicellular systems or, in cancer, to enable continuous adaptation to microenvironmental and therapeutic stress. The hypoxic CSC-stemgermline that coordinates the cancer-cell life cycle is continuously challenged and damaged by the hyperoxic microenvironment and by the excessively high oxygen levels encountered in blood and tissue, particularly above 6.0% oxygen. Irreversibly damaged stemgermline DNA must therefore be rapidly repaired or replaced. Dysfunctional stemgermlines are continuously replaced by functional “replacement clones” generated from somatic tumor cells or revitalized through hyperpolyploid DNA-damage-response mechanisms involving genome reconstruction. Following conversion, oxygen-resistant somatic cancer cells protect the stemgermline genome and may therefore function as a virtually unlimited genomic reservoir for the generation of new stemgermlines and CSC clones. The large spectrum of intermediate and transient phenotypes arising during both conversion processes contributes to the intratumoral heterogeneity characteristic of cancer cell populations.

Article
Medicine and Pharmacology
Oncology and Oncogenics

André Araujo de Medeiros Silva

,

Bruno Augusto Alves Martins

,

Oswaldo de Moraes Filho

,

Antonio Carlos Nóbrega dos Santos

,

Camila Oliveira Barbosa

,

Romulo Medeiros de Almeida

,

Tuane Colles

,

João Batista de Sousa

Abstract: Early-onset colorectal cancer (EOCRC) may differ clinically and oncologically from later-onset disease. This retrospective cohort study compared surgically treated patients with stage I–IV colorectal adenocarcinoma diagnosed at age < 50 vs. ≥ 50 years at a tertiary center between 2010 and 2020. Clinical, pathological, perioperative, and oncological outcomes were compared. Survival was evaluated using Kaplan–Meier analysis and Cox proportional hazards regression. Of 434 patients, 78 (17.97%) were aged < 50 years and 356 (82.03%) were aged ≥ 50 years. Mean (SD) follow-up was 35.59 (16.27) months. Patients aged < 50 years had shorter hospital stays (prevalence ratio [PR], 0.11; 95% CI, 0.01–0.21; p = 0.0336) but exhibited a higher prevalence of undifferentiated tumors (PR, 2.38; 95% CI, 1.18–4.78; p = 0.0147) and a 93% higher risk of recurrence (hazard ratio [HR], 1.93; 95% CI, 1.00–3.72; p = 0.0483) than those aged ≥ 50 years. No significant age-related difference was observed in overall survival, symptom–to–diagnosis interval, or pathological stage. EOCRC was associated with undifferentiated histology and a higher risk of disease recurrence. Further studies incorporating treatment information and molecular tumor characteristics are needed to clarify the independent prognostic significance of age in EOCRC.

Review
Medicine and Pharmacology
Oncology and Oncogenics

Ioana-Carmen Brie

,

Maria Perde-Schrepler

,

Piroska Virag

,

Cristina Balan

,

Cristina-Elena Gheara

,

Istvan Laszlo

,

Daniela Martin

Abstract: The intersection of radiotherapy and immunology has emerged as a highly promising frontier: localized radiotherapy can act as an in-situ vaccine, triggering prompt systemic anti-tumor responses. Carbon ion radiotherapy (CIRT) outperforms conventional photon radiotherapy (XRT) by delivering a highly concentrated dose to the target volume while minimizing collateral damage to adjacent healthy structures and preserving peripheral immune tissues. Emerging preclinical and clinical data indicate that CIRT possesses ex-traordinary immunomodulatory potential. High-LET carbon ion irradiation strongly drives immunogenic cell death (ICD), promotes mature dendritic cell antigen presentation, and strongly upregulates the cGAS–STING signaling cascade, shifting the TME from a "cold" immunosuppressive state to a "hot" immunostimulatory environment. Recent find-ings also show that carbon ions potently trigger non-apoptotic cell death modalities, fer-roptosis, necroptosis, and autophagy, which amplify ICD. When combined with IT, this triggers a potent synergistic effect that targets both local tumor recurrence and distant me-tastases. However, clinical translation faces critical issues, including patient selection and optimal dosing and scheduling. This review synthesizes key preclinical breakthroughs and emerging clinical data on CIRT combined with IT, exploring the molecular mecha-nisms underlying the synergy of this combination. We also discuss perspectives and fu-ture directions needed to optimize this promising therapeutic strategy.

Review
Medicine and Pharmacology
Oncology and Oncogenics

Mikel Portu

,

María Cotaina

,

Ángel Fernández-Rebollo

,

Laura Mas Grillo

,

Carlos Reyes

,

Alberto Breda

,

Josep Maria Gaya Sopena

,

Núria Serra Cabañas

,

Carme Facundo Molas

,

Lluís Guirado

+4 authors

Abstract: Systemic treatment of advanced renal cell carcinoma (RCC) after kidney transplantation requires balancing cancer control against allograft injury and immunosuppression. We searched PubMed, Ovid Embase, Scopus, Web of Science, and ClinicalTrials.gov in April 2026, with reruns on 13 August and 19 October 2026. We separated RCC-specific transplant reports from mixed-cancer transplant and non-transplant studies. Direct evidence comprised mainly case reports and retro-spective cohorts with incomplete outcomes and possible overlap. No prospective kidney-transplant-specific RCC study was identified. Vascular endothelial growth factor receptor–targeted tyrosine kinase inhibitors achieved tumor control in selected reports, but renal toxicity and interactions limited safety conclusions. Indications for mechanistic target of rapamycin in-hibitors (RCC treatment or immunosuppression) were often unclear. Concurrent therapies com-plicated response attribution. Immune checkpoint inhibitor outcomes ranged from tumor control with preserved graft function to rejection, irreversible graft loss, dialysis, graft intolerance, or nephrectomy. An unvalidated multidisciplinary framework integrates tumor site and lineage, histology, performance status, immunosuppression, and patient priorities. It distinguishes func-tioning or failing grafts, irreversibly failed retained grafts, and absence of allografts, states that change treatment trade-offs and outcome interpretation. Comparative evidence establishes nei-ther a preferred RCC sequence nor a graft-protective immunosuppressive regimen. Prospective studies should prioritize paired, state-specific cancer and transplant outcomes.

Review
Medicine and Pharmacology
Oncology and Oncogenics

Manish Adhikari

,

Huan Han

,

Nandini Shyamala

,

Malavika Shylesh

,

Gemma Martin

,

Sabiha Bano

,

Alejandra Calderon

,

Yuan Pan

,

Michael Huang

,

Nicole M Brossier

Abstract: Brain tumors have now surpassed leukemia to become the most common malignancies in childhood. Gliomas, a subset of primary central nervous system (CNS) tumors characterized by glial morphology, are the most prevalent of these tumors and can be either high- or low-grade. Prognosis and therapeutic approaches significantly differ between high-grade and low-grade gliomas, with generally poor survival rates for pediatric high-grade gliomas (pHGG) and more favorable outcomes for low-grade gliomas (pLGG). Historically, treatment has consisted of maximally safe surgical resection with or without radiation or chemotherapy, with the therapeutic plan dictated by age, tumor histology, grading and the extent of resection. However, extensive investigation into the molecular drivers of tumorigenesis over the last two decades has improved our understanding of glioma biology, resulting in changes to the classification criteria for these tumors as well as the development of new therapeutic agents targeting critical oncogenic pathways. This has begun to shift clinical practice for some tumor types, such as BRAF-altered LGG. In this review, we summarize our current classification of pediatric gliomas as well as their pathogenesis and treatment, with a particular focus on how biological insights have led to changes in current clinical practice, as well as how ongoing studies in tumor biology may evolve into the next generation of novel treatment strategies.

Review
Medicine and Pharmacology
Oncology and Oncogenics

Majid Ayaz

Abstract: Protein abundance helps identify candidate cancer targets. Their therapeutic relevance depends on the protein’s molecular state, its role in the tumor, and how the treatment acts on it. This review synthesizes evidence from quantitative proteomics, protein interaction mapping, structural analysis, genetic perturbation, and pharmacological studies. Preclinical examples involving epidermal growth factor receptor trafficking, hexokinase 2 scaffolding, chromatin complex assembly, and protein turnover illustrate how localization, binding partners, and post-translational modifications shape protein function. Studies of targeted degraders and molecular glues show why target engagement, ubiquitin ligase recruitment, and protein loss require separate verification. Clinical responses to revumenib in genetically defined acute leukemias support targeting the menin–KMT2A interaction, while acquired MEN1 mutations reveal a mechanism of resistance. Trastuzumab deruxtecan in HER2-low breast cancer illustrates a distinct use of protein expression to guide patient selection when the target serves as a delivery antigen. We propose a framework that evaluates protein expression, physical interaction, functional dependence, drug mechanism, and clinical benefit as distinct forms of evidence. The framework matches validation experiments and patient-selection biomarkers to the therapeutic modality. Confidence in a target is greatest when independent evidence connects the proposed mechanism to a cancer-relevant effect at achievable and tolerable drug exposures.

Brief Report
Medicine and Pharmacology
Oncology and Oncogenics

Alex Soloniuk

,

Drew Blake

,

Gary Yu

,

Udochukwu Oyoyo

,

Isaac Kremsky

,

Rajeev Nowrangi

,

Chao Zhang

,

Ravi Raghavan

,

Marlon Maus

,

Yan Chen Wongworawat

Abstract: As newer neural-network methods are applied to survival analysis, it is important to determine whether they improve prediction in relatively small clinical datasets. Our study compared model discrimination between conventional Cox regression and a DeepSurv neural network implemented in PyTorch to predict survival in historical TCGA glioblastoma patients with reported IDH-wildtype status. Both models used expression of the same four genes: OSMR, HOXC10, SCARA3, and SLC39A10. The primary measure of model performance was the C-index, with time-dependent AUC and Brier prediction error at one year as secondary measures. Age and sex were added in exploratory analyses to assess changes in performance. DeepSurv did not outperform conventional Cox regression in the main 139-patient four-gene analysis, returning a C-index of 0.567 compared with 0.591 for the refitted Cox model. The fixed published score developed by Cao et al. using the same genes returned a C-index of 0.614. Because the Cao score was developed using overlapping TCGA data, it served as a contextual benchmark rather than an independent validation. Adding age and sex yielded small numerical increases in the main-cohort C-index (DeepSurv, 0.577; Cox, 0.597). These findings show no observed advantage from the tested neural network over Cox regression in this internal comparison. Potential explanations that are not explored in this study but can be theorized are data missingness, overfitting, and limited data set size. The small historical cohort and lack of independent validation limit broader conclusions or clinical use at this time.

Article
Medicine and Pharmacology
Oncology and Oncogenics

Rahul Lakhotia

,

Disha Dalela

,

Max J. Gordon

,

Christopher Melani

,

Stefania Pittaluga

,

Sarah Evans

,

Elaine S. Jaffe

,

Mark Roschewski

,

Wyndham H. Wilson

Abstract: PD-1 is an inhibitory receptor on T cells that, when bound by PD-L1 or PD-L2, suppresses anti-tumor immunity. Tumors can exploit this pathway through overexpression of PD-L1, often driven by 9p24.1 chromosomal alterations. Within aggressive lymphomas, Chromosome 9p24.1 alterations occur in approximately 60% of mediastinal gray zone lymphoma (MGZL) cases, 14% of non-germinal center B-cell (non-GCB) diffuse large B-cell lymphomas (DLBCL), and over 50% of primary central nervous system (CNS) lymphoma and primary testicular lymphoma (PTL) cases. Outcomes for relapsed or refractory disease remain dismal across these histologies. Given the frequent chromosome 9p24.1 alterations in these lymphomas, PD-1/PD-L1 inhibition represents a rational therapeutic strategy in these malignancies. We conducted a single-institution, open-label, phase 2 study of time-limited pembrolizumab monotherapy 200 mg every 21 days for up to 2 years (35 cycles) in patients with relapsed or refractory MGZL, primary CNS lymphoma, or DLBCL subtypes that share biologic features with primary CNS lymphoma, including PTL and non-GCB DLBCL with extranodal involvement. Eligible patients were aged ≥14 years with adequate organ function and no prior anti-PD-1/PD-L1 therapy. Disease assessment was performed via CT and/or MRI at baseline, after cycles 2, 6, 13, 17, 26, and 35. The primary endpoint was overall response rate (ORR); secondary endpoints included safety, progression free survival (PFS), and overall survival (OS). The study was terminated early due to slow accrual, and 11 patients were evaluable for response. Patients had a median of 2 prior lines of therapy and histologies included 5 primary CNS lymphoma, 2 MGZL, 2 non-GCB DLBCL without CNS involvement, and 2 non-GCB DLBCL with secondary CNS involvement. Responses were observed in two patients: 1 patient with PCNSL with a partial response and 1 patient with MGZL with a CR that was ongoing at 3 years. Overall, the 2-year PFS was 9.1% and the 2-year OS was 64%. No unexpected toxicities were observed. Single-agent pembrolizumab had limited activity in relapsed or refractory extranodal DLBCL including PCNSL. In PCNSL, this may party reflect the immunosuppressive tumor microenvironment, which can impair effective antitumor T-cell responses despite frequent activation of the PD-1/PD-L1 pathway. Clinical factors may also contribute, as even limited CNS progression can cause significant neurologic symptoms and create an urgent need for disease control, potentially narrowing the therapeutic window for agents with delayed response kinetics such as PD-1 inhibitors. However, a durable CR was observed in the one MGZL patient treated, supporting continued investigation of this treatment in select LBCL subtypes.

Essay
Medicine and Pharmacology
Oncology and Oncogenics

Chinthalapally V. Rao

,

Hiroshi Yamada

Abstract: Cancer remains the most frequently cited disease relevance in basic and medical biology research. Yet the path from academic discovery to clinical application is often poorly understood, and significant gaps persist between academia and industry in both mindset and knowledge of the drug development process. This article outlines the essential components of contemporary preclinical cancer drug development to better equip academic researchers and strengthen the competitiveness of cancer-focused proposals. Our goal is to help bridge the translational divide, streamline the progression of academic innovations toward industry, and ultimately improve the success rate of candidate therapeutics by reducing attrition in the preclinical-to-clinical transition.

Article
Medicine and Pharmacology
Oncology and Oncogenics

Özlem Yersal

,

Büşra Niğdelioğlu

Abstract: Background and Objectives: Insomnia is a prevalent yet underrecognized symptom in patients with prostate cancer, and evidence in patients receiving systemic treatment is limited. We assessed the prevalence of insomnia and its associated factors in this population. Materials and Methods: In this two-center, cross-sectional study, insomnia was assessed with the Turkish version of the Insomnia Severity Index (ISI) in patients with metastatic prostate cancer receiving systemic treatment. Insomnia was defined as an ISI score ≥ 8 and clinical insomnia as an ISI score ≥ 15. Results: Among 110 patients, insomnia was present in 52 (47.3%) and clinical insomnia in 15 (13.6%). Pain (adjusted OR, 7.06; 95% CI, 2.31–21.59; p = 0.001) and a higher last prostate-specific antigen (PSA) level (OR per 10-fold increase, 1.47; 95% CI, 1.02–2.12; p = 0.040) were independently associated with insomnia. Clinical insomnia was more frequent in patients with visceral metastasis (50.0% vs. 9.4%; p = 0.008). Insomnia did not differ by treatment group or time on androgen deprivation therapy. Conclusions: Nearly half of these patients have insomnia, associated mainly with pain and active disease. Routine insomnia screening and pain management are warranted.

Review
Medicine and Pharmacology
Oncology and Oncogenics

Denise Drittone

,

Monia Specchia

,

Luisa Esposito

,

Eva Mazzotti

,

Bruno Carlesimo

,

Federica Mazzuca

Abstract: The blood–brain barrier (BBB) limits systemic treatment of glioblastoma and brain metastases. Electroporation-based therapies apply short, high-intensity electric pulses that transiently permeabilize cell membranes or ablate tissue. Electrochemotherapy (ECT) combines reversible electroporation with chemotherapy, markedly enhancing bleomycin cytotoxicity, whereas irreversible electroporation (IRE) and its high-frequency variant (H-FIRE) induce non-thermal ablation and transiently disrupt the BBB in preclinical models. This narrative review critically examines the current evidence and identifies priorities for clinical translation. The available data remain predominantly preclinical. In rat gliomas, ECT delivered through a dedicated intracranial electrode achieved complete tumor eradication in 69% of treated animals, with effects largely confined to the target region. IRE and H-FIRE have proved technically feasible in dogs with spontaneous intracranial tumors, and H-FIRE has prolonged survival in rodent glioma models. Clinical experience is minimal: a non-invasive approach combining transcranial magnetic stimulation with bleomycin was withdrawn before patient enrollment, and the only identified trial of intracranial ECT for brain metastases was terminated for slow recruitment without published results. Major barriers include the lack of human safety and efficacy data, of intracranial electrodes approved for clinical use, and of validated treatment-planning workflows, together with uncertain recruitment feasibility. We also discuss how intracranial ECT might complement central nervous system (CNS)-active systemic therapies in patients with limited intracranial progression and controlled extracranial disease. Although most evidence derives from glioma models, we propose that selected patients with brain metastases recurring after stereotactic radiosurgery represent a rational population for initial pilot studies.

Review
Medicine and Pharmacology
Oncology and Oncogenics

Javed Akhtar

,

Muhammad Imran

,

Jiahe Wang

,

Imran Sajid

,

Guanyu Wang

Abstract: Cells with similar endpoint measurements can have different biochemical response histories. Time-lapse single-cell Förster resonance energy transfer (FRET) imaging can distinguish these histories and test their relationship to metabolic function and cancer-cell fate. We connect FRET biophysics, biosensor design, and quantitative measurement to interpret cellular heterogeneity in metabolic dysfunction and cancer drug resistance. We emphasize corrected sensitized emission FRET imaging, distinguish corrected ratios from physical transfer efficiency, and describe controls for reporter specificity, temporal fidelity, and reproducibility. In metabolism, FRET imaging can reveal graded or bistable behavior and characterize sensitivity, response amplitude, history dependence, and coupling between signaling and substrate handling. In cancer, time-lapse signaling measurements paired with independent cell-fate outcomes can distinguish incomplete inhibition, adaptive recovery, and survival despite sustained pathway suppression. Cell culture, organoid, and intravital studies illustrate these capabilities and limits. Linking calibrated response histories to independent functional outcomes provides a robust foundation for candidate dynamic biomarkers. Integrating trajectory features with molecular profiles using machine learning could identify candidate predictors of treatment response. Future studies should test whether these dynamic features improve compound selection, combination design, and treatment schedules beyond baseline activity, initial inhibition, and endpoint measurements, with validation in independent patient-derived and in vivo models.

Article
Medicine and Pharmacology
Oncology and Oncogenics

Elizabeth E. Hopp

,

Zhen Ni Zhou

,

Christa Nagel

,

Steven Waggoner

,

Analisa DiFeo

Abstract: Folate receptor-α (FRα) is overexpressed in a subset of high-grade endometrial cancers, but the activity and molecular effects of the FRα-targeting antibody–drug conjugate mirvetuximab soravtansine (MIRV) in this disease are undefined. Mice bearing two FRα-positive high-grade recurrent high-grade endometrial cancer patient-derived xenografts (PDXs; UT42, UT150) were randomized to a single tail vein injection of MIRV (5 mg/kg) or phosphate-buffered saline (control); a separate UT150 cohort received a second dose on Day 9. Tumors harvested 24 hours after treatment underwent microarray profiling and Hallmark, KEGG, and Gene Ontology pathway scoring. MIRV significantly inhibited tumor growth in both models, and a second dose produced more durable suppression (P&lt;0.03). FRα protein expression was maintained after MIRV treatment. In both models, MIRV induced E2F target (z = 8.1 and 4.5) and G2/M checkpoint (z = 4.4 and 3.9) programs, consistent with DM4-induced mitotic arrest. MIRV also suppressed hypoxia (z = −6.4 and −11.6), epithelial–mesenchymal transition (EMT; z = −4.6 and −10.1), glycolysis and interferon-γ response programs. Genes reduced in both models (n = 117; 66 expected by chance) were enriched for TNFα/NF-κB, IL2–STAT5, EMT, and hypoxia signaling (FDR ≤ 0.002). These exploratory findings support evaluating MIRV-based combinations, including with anti-angiogenic agents, in endometrial cancer.

Article
Medicine and Pharmacology
Oncology and Oncogenics

Chen Shen

Abstract: Background: Metabolic reprogramming of tumor-associated macrophages (TAMs) drives tumor immune evasion, yet the spatial and subtype-level organization of TAM metabolism remains under-characterized. Methods: We re-analyzed public spatial metabolomics, spatial transcriptomics, and single-cell datasets using autocorrelation-corrected spatial statistics, patient-level testing, and replication across breast, lung, colorectal, liver, and brain tumor data. Results: TAMs formed the most spatially clustered transcriptional module in breast tumor sections. TAM-dense regions were robustly coupled to iron handling (ρ = 0.568), surviving gene-overlap, cell-abundance, and erythrocyte/vascular-exposure controls, whereas apparent glycolysis and lipid-uptake links did not survive spatial or abundance correction. In lung adenocarcinoma, subtype comparisons were confounded by tissue origin; within tumor tissue, two differences persisted across patients (higher lipid uptake in C1QC⁺ and higher iron handling in FOLR2⁺ TAMs). A reported SPP1⁺-versus-C1QC⁺ polarity recurred at cell level across cancer types but not at patient level. Mitochondrial DNA tracing detected clonally expanded, metabolically hyperactive TAMs in two of four evaluable samples. Conclusions: TAM metabolism is spatially organized and subtype-specific, with iron handling as the most robust territorial coupling, supporting spatially stratified, subtype-aware design of metabolism-targeting trials.

of 124